Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. - Wikidata - awgldk - TriplyDB

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer.

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer.

http://www.wikidata.org/entity/Q33378863

about

Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells Role of targeted therapy in metastatic colorectal cancer Oral drugs in the treatment of metastatic colorectal cancer.Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis.Phase I trial of oxaliplatin plus S-1 chemotherapy in patients with metastatic colorectal cancer.A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix.A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer.Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer.Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer.A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study.Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer.Efficacy of S-1 in colorectal cancer.Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity.S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial).Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer.The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer.Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases.Irinotecan Plus S-1 Followed by Hepatectomy for a Patient with Initially Unresectable Colorectal Liver Metastases, Who Showed Severe Drug Rash with Oxaliplatin Plus 5-FU and Leucovorin (FOLFOX).Pathological complete response of colorectal liver metastases following chemotherapy with S-1 and oxaliplatin (SOX) in combination with bevacizumab: A case report.Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer.Complete Response of Para-Aortic and Lateral Pelvic Lymph Node Recurrence of Rectal Cancer Treated to S-1 Monotherapy.Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/recurrent gastric cancer previously untreated with chemotherapy.The short-term outcomes of induction SOX (S-1 + oxaliplatin) ± cetuximab chemotherapy followed by short-course chemoradiotherapy in patients with poor-risk locally advanced rectal cancer.A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer.Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report.Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI).

P2860

Q24302022-4A00A629-6809-49CF-971C-D9579384DF2A Q28068817-A231DAD4-BF17-4A6E-862D-01CC4FC3B55E Q30251387-075B9685-3A82-4853-A81D-516DB0F6242E Q33386875-227DC97A-63C5-4104-BC86-9504E510DE62 Q33391561-27DD8D89-12EC-47A7-A9B1-B6389CBF0008 Q33403227-BA7F31BD-77B5-42E2-8EB7-9B57EF8616D7 Q33406474-CC8488E8-D344-4F0C-A7AD-9D5C4272A862 Q33413523-8C3DD45C-3D3B-4FBC-B7CC-A8BEE422C474 Q33422070-6C6C8BBA-5B04-49AC-ABF3-8BE57404FC37 Q33425826-5B5E5FA6-171D-43FB-924F-2AB2160E6537 Q33435747-9B5138CC-9A4D-49CF-871B-78AAB61CA76D Q33436476-355ECC5E-A03A-4128-8727-69190985ECA6 Q33751177-C2AF17AD-0D77-45E6-AAE7-F01CC1BCBDB1 Q34429445-37AB4936-1E80-47E0-A44F-D7B9E61A0F9C Q34627947-F019B71F-299D-46F4-8B57-F90103FFE522 Q34897322-2AE58AA1-A21C-4092-8870-52D7F58BA0E4 Q35033392-AA84DAEB-F9C5-417A-B43F-74D004CDE460 Q37561374-38427F26-AB46-40B4-B29D-5077DFA88649 Q38473718-CBCABCED-8F2D-44D1-87D0-55AC3B8F378D Q38551668-76B49F84-4584-40B2-AE06-8A0AA0037D78 Q39786290-AC5BD10B-D385-4642-93C6-65C46731B049 Q42011313-1C317DAC-C815-49EA-825A-EB8867D0305F Q42259474-BCA0B148-474B-474F-9527-0FAD14081381 Q45928691-B1CCFFA0-C15A-4D6D-BB51-7AB6D6CC63D9 Q46098962-97634C7A-7CA5-4DBE-9A0B-A78B3197EC73 Q47178340-972437CC-A899-41B3-B22A-4725FDE402A8 Q53236494-C376B2A7-E5AE-438B-BE2A-11A198F81FC7 Q53648255-B0C75BCC-A5EB-40EA-8938-544084493CBC Q54311320-EB092CE3-F003-442C-A0B6-8529FBAECCEB Q55005321-C81F3958-DE62-4E7D-8BA5-8E5ED40F201A

P2860

Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer.

http://www.wikidata.org/entity/Q33378863

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Phase I/II study of oxaliplati ...... metastatic colorectal cancer.

@ast

Phase I/II study of oxaliplati ...... metastatic colorectal cancer.

@en

type

label

Phase I/II study of oxaliplati ...... metastatic colorectal cancer.

@ast

Phase I/II study of oxaliplati ...... metastatic colorectal cancer.

@en

prefLabel

Phase I/II study of oxaliplati ...... metastatic colorectal cancer.

@ast

Phase I/II study of oxaliplati ...... metastatic colorectal cancer.

@en

P1433

Q33378863-DF61E001-47C5-4C43-9960-F04559F94FBC

P1476

Q33378863-F41D3124-2157-402B-9182-6093252A4D3A

P2093

Q33378863-01A6A0FF-4FE6-43C6-AD2F-9B44BFB60948

Q33378863-28215603-7564-4D23-B940-3DBFDC385B59

Q33378863-7975AE61-9AFE-48E2-A4AE-0AB7114F0E39

Q33378863-799CA14E-9051-4BEA-9BC1-980F5485059D

Q33378863-952A3BD6-80E3-41CF-924A-138874715AF5

Q33378863-C82E9A36-5BA2-4D41-A025-87C2EB23DD6C

Q33378863-CB45653B-EB56-464C-BC40-CA3C7F59E2A1

Q33378863-CFCC0F68-1BF1-47C3-8646-D8AA20C7A7CB

Q33378863-E5F4F992-3F73-4CAB-9ACA-216CFB6B8B14

P2860

Q33378863-01C76C37-B64A-4B1A-A179-2A953746D406

Q33378863-02520774-FE9E-49C4-B4B2-A8BA9F8F2B23

Q33378863-183D0487-7F6E-4BE8-91A3-58550E582C17

Q33378863-203251F7-EEC0-496B-BC6A-DF51410F92BD

Q33378863-26B3A411-6553-4F94-98FE-264A913F62C0

Q33378863-471E4F52-E92A-4707-A94A-69B19B13FAB1

Q33378863-565F7A4F-1820-4C13-8AFF-26C5FC10F8E6

Q33378863-60132A83-B5B7-4132-A37A-A2DDE07348ED

Q33378863-69D20496-B0DA-44EC-B479-18F07ACE310D

Q33378863-6C53C640-AAC6-4899-B1E1-9E9AB80D3D4D

P2888

Q33378863-33E26AAC-B8DF-4568-8D6E-D6C130482F4D

P304

Q33378863-6A088D56-DB0A-48D2-B627-3937EAB6172F

P31

Q33378863-0F49AD82-82C0-4DA2-8F79-AD0EA4BEE966

P356

Q33378863-6D882ED0-F05C-49CE-8945-65CDEF5F4FF0

P407

Q33378863-61F0BFD1-6651-49B6-8FB3-2A89F7E0612F

P433

Q33378863-EC928D2F-E144-454D-8578-3490CE195086

P478

Q33378863-08889856-0CF5-4314-97D5-19C23CAACB8B

P577

Q33378863-D704BFF9-E715-4BBD-A733-1B25454830C6

P5875

Q33378863-7EAF8BCD-BFA6-41C1-A0F6-0CF43C2E1240

P6179

Q33378863-349F3BCA-6C83-45D4-B8C5-57E25CC6EB10

P698

Q33378863-EC01EF07-13D9-43CB-B328-C629613C6388

P921

Q33378863-E0607EBF-31ED-4924-82EE-FEE5C6606F42

P932

Q33378863-5EEAE78F-29DB-410D-90D4-065F750454DE

P356

P1433

British Journal of Cancer

P1476

Phase I/II study of oxaliplati ...... metastatic colorectal cancer.

@en

P2093

A Ohtsu

http://www.w3.org/2001/XMLSchema#string

K Shirao

http://www.w3.org/2001/XMLSchema#string

M Tahara

http://www.w3.org/2001/XMLSchema#string

T Miya

http://www.w3.org/2001/XMLSchema#string

T Satoh

http://www.w3.org/2001/XMLSchema#string

Y Sasaki

http://www.w3.org/2001/XMLSchema#string

Y Shimada

http://www.w3.org/2001/XMLSchema#string

Y Tanigawara

http://www.w3.org/2001/XMLSchema#string

Y Yamada

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7).

Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.

Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group

Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.

Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial.

P2888

P304

1034-1038

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604271

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2008-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5531987

http://www.w3.org/2001/XMLSchema#string

P6179

1032321775

http://www.w3.org/2001/XMLSchema#string

P698

18319719

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

2275487

http://www.w3.org/2001/XMLSchema#string